Roth Capital Remains Bullish Following Ligand Pharma's (LGND) Supply Agreement with Gilead (GILD)
Tweet Send to a Friend
Roth Capital reiterated a Buy rating and $146.00 price target on Ligand Pharma (NASDAQ: LGND) following the company's announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
